To assess the value and timing of percutaneous transluminal coronary angioplasty (PTCA) after thrombolytic therapy for acute myocardial infarction (AMI), 586 patients in the Thrombolysis in Myocardial Infarction Study Phase II-A were randomized among three treatment strategies, one using immediate coronary arteriography followed by PTCA if appropriate (immediate invasive strategy group, n=195), a second that deferred angiography and PTCA for 18-48 hours (delayed invasive strategy group, n=194), and a third, more conservative, approach in which PTCA was used only if ischemia occurred spontaneously or at the time of predischarge exercise testing (conservative strategy group, n=197). Predischarge contrast left ventricular ejection fraction, the primary study end point, was similar among the patients in all three treatment groups and averaged 49.3%. The finding of a patent infarctrelated artery at the time of predischarge arteriography was equally common among the patients in the three groups (mean, 83.7%); however, the mean residual infarct artery stenosis was greater in the patients in the conservative strategy group (67.2%) as compared with the patients in the immediate invasive (50.6%) and the delayed invasive strategy groups (47.8%) (p<O.OOl). Immediate invasive strategy led to a higher rate of coronary artery bypass graft surgery (CABG) after PTCA (7.7%) than did delayed invasive and conservative strategies (2.1% and 2.5%, respectively; p<0.01). Furthermore, among patients not undergoing CABG during the first 21 days, blood transfusion of more than 1 unit was used in 13.8% of the patients in the immediate invasive strategy group, 3.1% of the patients in the delayed invasive strategy group, and 2.0% of the patients in the conservative strategy group (p<0.001). At 1-year follow-up, the three treatment groups had similar cumulative rates of mortality (8.7%, pooled over all groups), fatal and nonfatal reinfarction (8.5%), combined death and reinfarction (14.5%), and CABG (17.2%), although the cumulative performance rate of PTCA remained higher in the invasive groups (immediate invasive strategy group, 75.8%; delayed invasive strategy group, 64.3%; and conservative strategy group, 23.9%; p<0.001). Thus, because conservative strategy achieves equally good short-and long-term outcome with less morbidity and a lower use of PTCA, it seems to be the preferred initial management strategy.
H igh-grade residual stenosis is common immediately after thrombolysis for acute myocardial infarction (AMI) and predicts subsequent reocclusion of the infarct-related artery.1 Based on earlier studies demonstrating that percutaneous transluminal coronary angioplasty (PTCA) is possible soon after starting thrombolytic therapy,2-6 it seemed reasonable to hypothesize that PTCA performed very early after symptoms of infarction might lower the probability of reocclusion, augment myocardial reperfusion, and aid in the salvage of ischemic myocardium. It was unclear, however, whether PTCA performed in the AMI setting (with altered clotting function and variable states of hemodynamic and arrhythmic instability) would be safer and more likely to preserve life and myocardium than a more conservative approach that reserved myocardial revascularization for only those patients who manifested recurrent ischemia.
Accordingly, the National Heart, Lung, and Blood Institute Thrombolysis in Myocardial Infarction (TIMI) II-A trial was undertaken to compare two invasive strategies, one using immediate PTCA when feasible (immediate invasive strategy) and the other See p 1707 using PTCA delayed by 18-48 hours (delayed invasive strategy), with a more conservative strategy of "watchful waiting" (conservative strategy) in patients with AMI treated with recombinant tissuetype plasminogen activator (rt-PA). A preliminary report of the results through 21 days of study entry for patients randomized to the immediate invasive and delayed invasive strategy groups has been published previously. 7 The purpose of the present study was to provide a comprehensive description of the TIMI II-A findings, including the following topics not addressed in the preliminary report: 1) outcome of the patients allocated to the conservative strategy group, 2) quantitative ventriculographic and coronary arteriographic analyses, 3) resting and exercise radionuclide ventriculographic findings at the time of hospital discharge and at 6 weeks' follow-up, and 4) survival, interim events, and additional procedures performed during 1 year after entry. Additionally, whereas individual clinic assessments of infarct-vessel patency and PTCA success were presented in the preliminary report, core radiographic laboratory assessment of these parameters is provided in the present study. Methods 
Study Design
A detailed description of the design of TIMI 1I-A has been previously published. 7 The principal objective of TIMI IT-A was to establish the feasibility and optimal timing of PTCA in patients receiving rt-PA for AMI. The primary study end point was contrast left ventriculographic ejection fraction at the time of hospital discharge, although a number of prospectively defined secondary end points were also assessed, including the value and success of protocol PTCA, predischarge infarct-vessel patency, exercise test performance, need for nonprotocol procedures (including coronary arteriography and coronary revascularization), and frequency of complications (including death, nonfatal reinfarction, and need for transfusion).
Patient Population
Between April 11, 1986 , and June 30, 1988, 3,534 patients were entered into TIMI II, of whom 586 were enrolled in the TIMI II-A substudy at seven participating clinical sites ("Appendix") ( Figure 1 ). Investigators at these sites had special interest and documented proficiency in PTCA for AMI. Eligible for TIMI II were patients less than 76 years old with ischemic chest pain of at least 30 minutes' duration and ST elevation of at least 1.0 mV in at least two contiguous electrocardiographic leads who gave informed consent, who could have rt-PA administered within 4 hours of onset of AMI symptoms, and in whom none of the previously described exclusion criteria were present.7
Administration of rt-PA, Heparin, and Aspirin
The rt-PA used in TIMI II was supplied by Genentech Inc. and prepared by the suspension culture technique (G11044). Study entry commenced when rt-PA infusion was initiated. In the first 195 patients, rt-PA was given as a dosage of 150 mg/6 hr; subsequently, because of an unacceptable frequency of hemorrhagic complications, the dosage was reduced to 100 mg/6 hr (391 patients),8,9 administered as an intravenous bolus of 6 mg and a constant infusion of 54 mg during the first hour, 20 mg during the second hour, and 5 mg during each of the next 4 hours. Before rt-PA administration, patients were prospectively classified according to myocardial infarction (MI) 4"risk status" as defined previously.7 Immediately after beginning rt-PA, a bolus of 5,000 USP units heparin was injected intravenously, followed by a 5-day constant infusion, initially at 1,000 units/hr but adjusted to maintain the activated partial thromboplastin time 1.5-2.0-fold the upper limit of normal. On day 6, 10,000 units s.c. heparin every 12 hours was begun and continued until the predischarge exercise test. In the first 127 patients, aspirin was given at a dose of 81 mg daily for 5 days beginning on the day of rt-PA administration and at a dose of 325 mg daily thereafter; subsequently, aspirin was initiated on day 2 rather than day 1. 
Initial Treatment Assignments
Unique randomization treatment allocation schedules were prepared by the TIMI Coordinating Center for each clinical center to ensure assignment of equal numbers of patients to the three treatment groups at each site. Assignment to the immediate invasive strategy, delayed invasive strategy, or conservative strategy group (Figure 2 ) was accomplished at each clinic using a security-protected 11 judgment that abrupt closure of involved vessel could cause catastrophic hemodynamic consequences. Standardized projections of the coronary arteries were recorded at baseline and again after PTCA. Full improvement after PTCA was defined as normal or improved flow in the infarct-related artery and both an absolute reduction in lumen stenosis by at least 20% and a final lumen stenosis of less than 60%. Partial improvement was defined as unchanged or improved flow with only one of the above changes in lumen stenosis.
Patients randomized to the conservative strategy group underwent routine coronary care unit management.10 Coronary arteriography in this group was discouraged until immediately before hospital discharge (days 8-10 after entry) unless there was the recurrence of ischemia refractory to progressive stepwise medical therapy with nitrates, [3-blockers, and calcium antagonists. In all groups, coronary artery bypass graft surgery (CABG) was limited to patients with pressing clinical indications and coronary anatomy more suitable for CABG than PTCA (i.e., left main coronary artery disease or advanced multivessel disease in which closure of the infarct-related artery would cause severe hemodynamic compromise).
Concomitant Care and Interim Events
Except for PTCA assignment, patients in each of the three treatment groups were managed identically. On the initial presentation, all patients received sublingual nitroglycerin, prophylactic lidocaine, and morphine. Unless there were contraindications, nifedipine 10-20 mg three times daily was administered for 96 hours. Unless contraindicated, metoprolol was administered after the predischarge contrast and radionuclide studies herein described, at 50 mg twice daily for 1 day, and then 100 mg twice daily for the next year. Guidelines for management of complications of myocardial infarction were specified within the TIMI In all analyses in this study, patients were included in the group to which they were randomized regardless of whether coronary angiography and PTCA were actually performed within the time specified for that treatment group. The results presented in this study are based on all data processed in the TIMI Coordinating Center as of August 7, 1989 .
Results

Baseline Characteristics
Of the 586 patients enrolled in TIMI II-A, 195 were allocated to the immediate invasive strategy group, 194 were allocated to the delayed invasive strategy group, and 197 were allocated to the conservative strategy group ( Table 1 ). The three randomized groups were similar with respect to age, race, and sex distribution. The majority (66.2%) of patients were classified as "not low risk," primarily because of the presence of anterior MI (52.0%), history of previous infarction (16.9%), or advanced age (13.0%). Despite randomization, slightly more patients in the immediate invasive strategy group were classified as "not low risk" (72.8%) as compared with the delayed invasive strategy (61.9%) and conservative strategy (64.0%) groups (p=0.05); however, the prevalence of the individual major risk factors (age, .70 years; previous MI; and anterior MI) were not significantly different among the three treatment groups. Intravenous rt-PA was initiated at a mean of 2.9 hours after onset of pain, at which time chest pain was still present in 86.7% of the patients. Performance of Coronary Arteriography and PTCA According to protocol design, the performance of coronary arteriography and PTCA differed significantly among the three groups. In the first group (immediate invasive strategy), coronary arteriography was performed within 2 hours of rt-PA initiation however, PTCA was actually attempted during this time window in 108 patients ( Figure 3 ). PTCA resulted in improvement in 89.8% of the patients in whom it was attempted in this group, and major complications within 24 hours of PTCA occurred in 4.6% of the patients in whom it was attempted ( Figure 4 ). Of the 19 patients who did not undergo coronary arteriography during the 18-48-hour window, five had died before invasive evaluation and 12 other patients had undergone urgent catheterization before 18 hours, which led to PTCA in 10 patients (one of whom also had subsequent CABG).
In the third group (conservative strategy), the intent was to perform coronary arteriography only at the time of hospital discharge (days [8] [9] [10] 3, and 5 days after entry, early coronary arteriography was performed in a cumulative 6.1%, 8.6%, and 12.2%, respectively, of the patients and was followed by PTCA in 4.1%, 5.6%, and 6.6% of these respective patients ( Figure 5 , left panel). Altogether, 17.8% of the patients in the conservative strategy group underwent coronary angiography before the scheduled hospital discharge catheterization, which led to PTCA in 7.1% of patients (14) and CABG in 3.0% of patients (six).
Of the 14 patients in the conservative strategy group who developed recurrent ischemia prompting early angiography followed by PTCA, PTCA resulted in improvement in 57.1%, including four of six patients who had an occluded infarct-related artery at the time of arteriography. During the 24 hours after PTCA, however, two patients (14.3%) in this group developed major complications ( Figure 4) . By contrast, in the 21 patients in the conservative strategy group who underwent PTCA after predischarge coronary arteriography but within 21 days of study entry, PTCA resulted in improvement in 90.4% of patients, including one of two patients who were found to have an occluded infarct-related artery. During the next 24 hours, major complications occurred in two patients (9.5%) ( Figure 4 ).
Rescue Angioplasty
In the immediate invasive strategy group, 29 patients underwent acute dilation of totally occluded vessels. Of the 29 patients, 93.1% had patent infarctrelated arteries after PTCA, and the 21-day mortality rate was 6.9%. Predischarge catheterization, however, in 24 of these patients showed that 20.8% of these "rescue PTCA" vessels had reoccluded. In contrast, a total of 67 patients (35 in the delayed invasive strategy group and 32 in the conservative strategy group) had occluded infarct-related arteries at the time of initial catheterization. Although PTCA was attempted in 21 of these 67 patients with recurrent ischemia, the great majority (n=41) of these patients were discharged without PTCA or CABG, and their 21-day mortality rate was 7.3%.
Performance of CABG
Bypass surgery was performed in 67 of 586 patients (11.4%) in the TIMI 11-A trial within 21 days of study entry, including 24 patients after attempted PTCA and 43 patients referred directly to CABG based on anatomic findings ( Figure 5, right panel) . Although the use of CABG for anatomy unsuitable for PTCA was comparable among the three groups (17, 12 , and 14 patients, respectively), there was significantly greater use of CABG after attempted PTCA in the immediate invasive strategy group (7.7% of patients) than in either the delayed invasive strategy group (2.1% of patients) or the conservative strategy group (2.5% of patients) (p=0.01).
The results of primary bypass surgery for PTCAunfavorable anatomy were quite good, with a 21-day mortality rate of 2.3% (one of 43 patients) and a perioperative infarction rate of 0.0%. On the other hand, the results of CABG after attempted PTCA were less satisfactory, with a 21-day mortality rate of 16.7% (four of 24 patients) and a perioperative infarction rate of 25.0% (six of 24 patients).
Patency of Infarct-Related Artery
The identity of the infarct-related artery, as determined from the first coronary arteriogram obtained on each patient, was similar among the three treatment groups (Table 2) . Protocol coronary arteriograms obtained at a mean of 1.4 and 32.8 hours after rt-PA initiation in the patients in the immediate invasive strategy and delayed invasive strategy groups, respectively, demonstrated patency (TIMI grade 2 or 3) of the infarct-related artery in 81.4% of the patients in the immediate invasive strategy group and 83.4% of the patients in the delayed invasive strategy group. Coronary arteriograms were obtained before hospital discharge (mean, 9.3 days after entry) in 80.5% of the TIMI IL-A patients and showed patency of the infarct-related artery in 81.1% of the patients in the immediate invasive strategy group, 84.0% of the patients in the delayed invasive strategy group, and 85.7% of the patients in the conservative strategy group (p=NS).
In the 126 patients without data regarding predischarge patency, reasons included death before angiography (38 patients), recent CABG (29 patients), patient refusal (25 patients), and miscellaneous other reasons (34 patients) . In an attempt to compensate for absence of predischarge coronary arteriography in some patients, those patients who underwent CABG (n = 29), those patients who had recurrent MI (n=4), or those patients who died before predischarge arteriography (n=38) were assumed to have occluded vessels, whereas the remaining patients (n=51) were assumed to have discharge patency unchanged from their earlier study (44 open and seven closed). With these imputations, patency could be estimated in 582 of the study patients (99.3%), with imputed predischarge patency rates of 71.8%, 72.7%, and 76.7% in the three treatment groups, respectively (p=NS).
Coronary arteriograms suitable for quantitative analysis of the infarct-related artery were available in 99.7% of the patients in the PTCA groups who underwent early protocol coronary arteriography, in all of the patients who underwent protocol PTCA, and in 97.5% of patients who underwent protocol predischarge coronary arteriography (Table 2) . On the initial arteriogram, the severity of the infarctartery stenosis was significantly greater in the patients in the immediate invasive strategy group than in the patients in the delayed invasive strategy group (79.9% vs. 75.2%,p=0.01), and the proportion of infarct arteries having stenosis of less than 60% was significantly lower (6.2% vs. 14.4%, p=0.01). Immediately after protocol PTCA, infarct-artery stenosis was reduced by an absolute 35.2% and 36.5%, respectively, in the two groups (p=0.65). At the time of hospital discharge, highly significant group. Specifically, the mean stenosis was less (50.6% differences in the severity of the residual infarctand 47.8% vs. 67.2%,p<0.001) and the percentage of vessel stenosis were observed between the patients in patients with a residual stenosis of less than 60% was the two PTCA groups and the conservative strategy greater (67.6% and 75.0% vs. 31.0%, p<0.001) for (Figure 6, upper panel) . Furthermore, end-systolic and end-diastolic volume indexes, cardiac index, and measurement of wall motion in the infarct and noninfarct zones, respectively, were similar among the three randomized groups (Table 3 and Figure 6, the patients in the three treatment groups at 21 days, 42 days, and 1 year after entry ( Figure 7 and Table 6 ). Death between 21 days and 1 year after entry in the patients in the immediate invasive strategy, delayed invasive strategy, and conservative strategy groups occurred in only 1.0%, 2.0%, and 2.6% of the patients, respectively. During the first 21 days after entry, CABG after PTCA was significantly more common in the patients in the immediate invasive strategy group than in the patients in the other two groups as were transfusions of more than 1 unit in patients not undergoing CABG (Table 6) . At both the 6-week and l-year follow-ups, the patients in the three randomized treatment groups reported similar activity levels, angina class, and frequency of rehospitalization.
The interim performance of CABG between the time of hospital discharge and 1 year after entry was similar among the patients in the three treatment groups and averaged 5.2% (Table 6 ). The cumulative performance of CABG throughout the first year after entry (including the initial hospitalization) was similar among the patients in the three groups and averaged 17.2% (Figure 7 ). The interim performance of PTCA between the time of hospital discharge and 1 year after entry was similar among the patients in the three groups and averaged 5.6% (Table 6 ). Between the time of entry to the study and 1-year follow-up, PTCA was performed in 75.8% of the patients in the immediate invasive strategy group, 64.3% of the patients in the delayed invasive strategy group, and 23.9% of the patients in the conservative strategy group (p<0.001).
At the 1-year follow-up, revascularization (PTCA or CABG, or both) had been performed in 84.4% of the patients in the immediate invasive strategy group, 72.3% of the patients in the delayed invasive strategy group, and 38.6% of the patients in the conservative strategy group (p<0.001).
Treadmill Exercise Test Findings at 1-Year Follow-up
Treadmill exercise tests were performed in 397 patients (67.7%) at the 1-year follow-up visit. Exercise duration, hemodynamics, and frequency of ischemic response were similar among the patients in the three treatment groups (Table 7) .
Discussion
The TIMI II-A trial demonstrates that patients receiving rt-PA therapy for AMI who are treated by an aggressive approach including either routine immediate (<2 hours) or delayed (18-48 hours) coronary arteriography followed by PTCA, if feasible, have no better global or segmental left ventricular function at the time of hospital discharge than patients managed by a more conservative approach in which coronary arteriography is delayed until hospital discharge and coronary revascularization is reserved for those patients with recurrent spontaneous or exercise-induced ischemia. Further, the conservatively managed patients have a similar proportion of patent infarct-related coronary arteries at the time of hospital discharge, similar rest and exercise EFs at the time of discharge and 6-week follow-up, and similar frequency of death, reinfarction, and rehospitalization during the subsequent year.
Rationale for Routine PTCA Residual atherosclerotic plaque and thrombus compromise coronary perfusion and facilitate reocclusion after thrombolytic therapy for AMI, leading many to believe that prophylactic PTCA in this setting might improve myocardial function. Thus, when it was demonstrated that PTCA could be performed during and after thrombolytic therapy, the policy of routine PTCA after thrombolytic therapy quickly became established at many hospitals. The Unlikely eplanations PATIENT SELECTION. If TIMI II-A had selected very-low-risk patients for study, a good outcome might have been expected regardless of the treatment strategy used. But the TIMI II-A patients were not in a low-risk stratum as evidenced by the fact that two thirds of the patients who entered the trial were at higher-than-usual risk for AMI mortality because of their age of more than 70 years, history of previous MI, or presence of an anterior MI (Table 1) . Patients were eligible for TIMI II regardless of the extent of left ventricular dysfunction if they were alert enough to provide written informed consent. Because rt-PA was available in most communities only through the TIMI II trial during the majority of the study enrollment period, there was considerable enthusiasm for referral of a wide spectrum of AMI patients to the trial, making a selection bias toward low-risk patients very unlikely.
On the other hand, the inclusion and exclusion criteria for TIMI II were designed to select ideal candidates for thrombolytic therapy, namely, patients with recent onset of symptoms of AMI, definite clinical and electrocardiographic criteria for AMI, and low anticipated risk of hemorrhagic complications. Accordingly, TIMI II did not address the selection of reperfusion interventions in other groups of patients, for example, those patients more than 75 years old, those patients presenting late or with either unstable angina or non-Q wave infarction, and those patients with contraindications to thrombolytic therapy. Although these groups of patients will require further study, their exclusion from TIMI II does not compromise the relevance of its findings to the care of the intended population. PTCA PERFORMANCE. If the patients randomized to the PTCA strategies had not received PTCA when indicated or if the results of PTCA had been poor, these facts might have explained why outcome in the invasive strategy groups failed to surpass that of the conservative strategy group. In the patients in the immediate invasive strategy and delayed invasive strategy groups, however, PTCA was performed within the protocol time window in 72% and 56% of the patients, respectively. Importantly, when PTCA was not performed, the reasons were consistent with good clinical judgment and common practice (generally, the lack of significant stenosis or the presence of disease better managed by CABG than by PTCA). Among patients receiving protocol PTCA, the procedure resulted in angiographic improvement (as assessed by the Radiographic Core Laboratory) in 77% of the patients in the immediate invasive strategy group and in 90% of the patients in the delayed invasive strategy group. (PTCA-related improvement was reported by the individual TIMI clinics as 84% in the patients in the immediate invasive strategy group and 93% in the patients in the delayed invasive strategy group.7) PTCA reduced the residual stenosis of the infarct artery by an average of 36% (absolute units) ( Table 2) ; these PTCA results are excellent by present standards.
ASSESSMENT OF LEFT VENTRICULAR FUNCTION. Left ventricular contrast EF at the time of hospital discharge was the primary end point of TIMI II-A. If this variable had been improperly or incompletely assessed, the interpretation of the study could have been biased. Direct measurement of contrast left ventricular EF was available in 80% of the study patients and averaged 49-50% in each of the three treatment groups (Table 3 ). In those patients without direct measurement of EF, we used radionuclide EF data (when available) and assigned an EF of zero to nonsurvivors; using these imputations, assessment of EF was possible in 95% of the study patients, but still there were no intergroup differences.
In an attempt to identify subgroups of patients among the treatment groups in whom EF might have differed, we examined patients with previous MI, with anterior MI, and classified as not low risk for any reason. Further, we assessed parameters of left ventricular function that might be more sensitive than global EF (e.g., end-diastolic and end-systolic volume, regional wall motion in the infarct zone, and resting and exercise radionuclide EF at the time of hospital discharge and at the 6-week follow-up); however, we could find no significant difference in these indexes of ventricular function among the patients in the three randomized treatment groups.
TIMING OF END-POINT ASSESSMENT. It might be argued that a hospital-discharge end point is too early to assess differences in outcome among the patients in the three treatment groups. Had the outcome of the conservative strategy been equivalent to the PTCA strategies during the initial hospitalization only to result in frequent relapses after hospital discharge, the advantages of this approach would be compromised. One-year follow-up data confirm, however, that not only is the mortality in the patients in the three groups similar at 1 year after entry (Table 6 ), but the risks of reinfarction alone or reinfarction and death are also similar ( Figure 7 and Table 6 ). The incremental mortality (1.9%) between the time of hospital discharge and 1-year follow-up in the TIMI II-A population is extraordinarily low, especially in comparison with a previous large trial of thrombolytic therapy without systematic revascularization that showed an incremental mortality rate of 6.5%, between the time of discharge and 1-year follow-up. 17 , 18 The frequency of repeat hospitalization, as well as the frequency of interim cardiac catheterization, PTCA, and CABG, was similar among the patients in the treatment groups throughout the first year of follow-up. From entry until the 1-year follow-up, the proportion of patients having CABG did not differ in the three groups. Overall revascularization procedures through 1 year of follow-up remained substantially fewer in the conservative strategy group because of the lower use of PTCA. TIMI I-A, PTCA was performed for clinically evident recurrent spontaneous ischemia in 9.1% of the patients in the conservative strategy group within the first 7 days after entry. Exercise testing suggested that the conservative strategy group was still more likely to have evidence of residual ischemic myocardium shortly before hospital discharge, a finding that generally predicts poorer 1-year survival. 19 These exercise test findings corresponded to quantitative coronary arteriography at the time of hospital discharge, which confirmed that the infarct-related arteries in this subgroup of patients had more severe residual stenoses than those patients in the invasive strategy subgroups.
The potentially deleterious consequences of these findings, however, were attenuated by the subsequent revascularization procedures that they prompted. PTCA, CABG, or both were performed after exercise testing in 14.4% of the patients in the conservative strategy group by 21 days, in 18.7% of the patients by 42 days, and in 27.3% of the patients by 1 year after entry. It is highly likely that targeting revascularization interventions to patients with spontaneous or exercise-induced ischemia minimized recurrent ischemic events in the conservative strategy group and rendered their outcome equivalent to the patients in the routine PTCA groups (in whom revascularization was performed less selectively). This finding is consistent with previous studies showing that limited exercise testing before the time of hospital discharge is capable of identifying groups of patients at high and low risk for recurrent ischemic events during the subsequent year.20-22 Waiting to perform revascularization until this test is performed seems to carry no increased risk of mortality or reinfarction for the patient. Furthermore, patients in whom revascularization was not used according to conservative strategy might have enjoyed an equally favorable outcome because of a subcritical (and clinically unimportant) residual infarct-artery stenosis, a lack of remaining viable myocardium in the infarct zone, or freedom from the small but finite risks accompanying revascularization. FAILURE OF RESCUE PTCA TO AUGMENT OVERALL OUTCOME. Patency of the infarct-related artery is observed 90 minutes after initiation of intravenous rt-PA treatment in approximately 75% of patients. 23 It has been proposed that routine immediate coronary arteriography would be useful in all patients receiving thrombolytic therapy to identify the 25% of patients with still-occluded infarct-related arteries and offer them rescue angioplasty.24 Although the TIMI 11-A trial was not designed specifically to test the benefit of rescue angioplasty, indirect information on this approach is available. Among the 29 patients in the immediate invasive strategy group who underwent acute dilation of totally occluded vessels, the primary success rate was 90% and the hospital mortality rate was 6.9%; however, the reocclusion rate of these rescue PTCA vessels was 20.8% at the time of predischarge angiography. In contrast, among the 67 patients with occluded infarct-related arteries on initial arteriography in the other two groups, most (61.2%) were discharged without PTCA or CABG and with a hospital mortality of 7.3%. Thus, from this assessment of patients in nonrandomized subgroups, rescue PTCA after rt-PA does not guarantee continued arterial patency at discharge, and the majority of patients with persistently occluded infarct-related arteries do well. This analysis does not include patients in the delayed invasive strategy and conservative strategy groups who died before catheterization (unknown patency status), and thus, a randomized trial of rescue PTCA might still be considered. But proponents should remember that routine early catheterization to detect occlusion exposes all patients (occluded or patent) to certain risks not associated with conservative strategy, which might compromise any benefits of rescue PTCA and yield overall results worse than with conservative strategy.
INCREASED COMPLICATIONS OF ROUTINE PTCA IN AMI. Goals of routine PTCA in AMI are to improve infarct-vessel caliber, lower rate of reocclusion, and improve ventricular function and patency rate at the time of discharge. In this study, however, infarct-related vessel patency was the same regardless of whether patients had been assigned to routine PTCA. Although early routine PTCA might have benefited some patients, these benefits might have been obscured by serious complications that occurred in other patients.
In both invasive strategy treatment groups, infarct vessels that had been patent after PTCA were occluded at the time of hospital-discharge catheterization (17.6% in the patients in the immediate invasive strategy group and 4.3% in the patients in the delayed invasive strategy group), consistent with previous reports documenting significant reocclusion frequencies in patients undergoing PTCA in the setting of AMI. (Figure 1 ), the TIMI 1I-A trial differed importantly in the following several design features: 1) the presence of the immediate catheterization or PTCA group (the immediate invasive strategy group), 2) the use of left ventricular EF as the primary end point rather than death or reinfarction, and 3) the requirement that all patients undergo coronary arteriography and left ventricular angiography before hospital discharge. Despite these differences, the results of the TIMI II-A trial were remarkably consistent with those of the larger TIMI TI main study, showing no benefit with the use of the invasive management strategy.
CONCOMITANT PHARMACOLOGICAL THERAPY. The role of ancillary pharmacological agents for patients receiving thrombolytic therapy for AMI is incompletely defined and the subject of ongoing clinical trials. Although the TIMI IT-A trial routinely used nifedipine and lidocaine, metaanalyses of the use of these agents for AMI in the prethrombolytic era have shown no benefit.29 These drugs, however, have not been adequately evaluated in the setting of thrombolytic treatment for AMI, and it is unknown whether nifedipine might be useful when PTCA is contemplated and whether lidocaine might be protective against ventricular arrhythmias occurring in the setting of reperfusion.
Intravenous heparin, used routinely after rt-PA initiation in TIMI IT, has been demonstrated in two recent controlled trials30'31 to promote infarct vessel patency at 7-72 hours after rt-PA initiation. Aspirin reduces the incidence of acute coronary thrombosis in patients undergoing PTCA32,33 and also reduces mortality synergistically with intravenous streptokinase in patients with AMI. 34 In TIMI TI-A, aspirin was begun on the day of rt-PA initiation in one third of the patients and on the subsequent day in the remainder of the patients. It is conceivable that if aspirin had been initiated on day 1 in all patients, the incidence of reocclusion in patients in the immediate invasive strategy group undergoing PTCA might have been lower but possibly at the risk of more hemorrhagic complications. Clinical Implications
The TIMI TI-A trial demonstrates that routine immediate PTCA in patients receiving rt-PA for AMI is associated with significant morbidity as compared with a less aggressive strategy of delaying the PTCA for 18-48 hours. Routine immediate or delayed early catheterization followed by PTCA, however, is not required to preserve ventricular function in patients receiving rt-PA for AMI. Instead, patients can be safely managed by a conservative policy of watchful waiting, followed by predis-charge exercise testing and coronary arteriography to evaluate ischemia. The TIMI II-A experience suggests that during the first 7 days, coronary revascularization for clinically evident recurrent ischemia will be required in approximately 10% of these patients. Although the conservatively managed patients have more severe infarct-vessel stenoses at the time of predischarge catheterization and a higher likelihood of a positive exercise test (leading to coronary revascularization in another 15% of the patients during the next 2 weeks), the frequency of major events (i.e., death and reinfarction) over the subsequent year is similar to patients managed with routine PTCA. Because the conservative approach achieves equally good short-and long-term outcome with less morbidity and a lower use of PTCA, it seems to be the preferred management strategy.
